Investor Relations
Abcam IR Home
Share price & chart
Reports & accounts / Financial Calendar
Regulatory news (RNS)
Contacts & advisors
Governance
CSR statement
Directors
Major shareholders
Other Documents
The Abcam story
About research antibodies
Abcam company news
Main Abcam website

REG - ABCAM Plc - PDMR Shareholding

 
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100430:nRSd1884La
RNS Number : 1884L
ABCAM Plc
30 April 2010 
 
 For immediate release  30 April 2010  
 
 
ABCAM PLC 
 
("Abcam" or "the Company") 
 
PDMR Dealings 
 
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online
catalogue, has been notified that on 29 April 2010, Mark Bushfield, a PDMR of the Company, purchased 470 ordinary shares of
1 pence each in the Company at a price of 1201p per share. Following this transaction, Mr Bushfield's total beneficial
interest in the Company is 555 ordinary shares representing approximately 0.002 per cent. of the current issued share
capital of the Company. 
 
For further information please contact: 
 
 Abcam                                              + 44 (0) 1223 696000   
 Jonathan Milner, Chief Executive Officer                                  
 Jeffrey Iliffe, Chief Financial Officer                                   
                                                                           
 Numis Securities                                   + 44 (0) 20 7260 1000  
 Michael Meade / Nick Westlake - Nominated Adviser                         
 James Black -  Corporate Broking                                          
                                                                           
 Buchanan Communications                            + 44 (0) 20 7466 5000  
 Mark Court / Stasa Filiplic                                               
 
 
Notes for editors: 
 
About Abcam plc 
 
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with
subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under
the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related
products to academic and commercial users throughout the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the
antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies
in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now
has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are
antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies. 
 
This information is provided by RNS
The company news service from the London Stock Exchange 
 

---

back to RNS news